4//SEC Filing
Bolte Axel 4
Accession 0000950170-25-094096
CIK 0001693011other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 7:07 PM ET
Size
10.9 KB
Accession
0000950170-25-094096
Insider Transaction Report
Form 4
Bolte Axel
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-07-01−159,187→ 0 totalExercise: $2.77Exp: 2030-04-22→ Common Stock (159,187 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-07-01−234,176→ 0 totalExercise: $2.02Exp: 2029-06-19→ Common Stock (234,176 underlying) - Disposition from Tender
Common Stock
2025-07-01$4.00/sh−423,926$1,695,704→ 0 total
Footnotes (3)
- [F1]This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger")
- [F2]Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
- [F3]Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
Documents
Issuer
Inozyme Pharma, Inc.
CIK 0001693011
Entity typeother
Related Parties
1- filerCIK 0001579247
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 7:07 PM ET
- Size
- 10.9 KB